Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer stage and outcome by array-based comparative genomic hybridization.

Ekaterini Blaveri1, Jeremy L Brewer, Ritu Roydasgupta

  • 1Department of Laboratory Medicine, University of California San Francisco, San Francisco, California 94143-0808, USA.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 6, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining the combinatorial nature of gene modules in prostate cancer underlying lineage plasticity and metastasis.

Research square·2026
Same author

Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous.

JAMA oncology·2026
Same author

Development and Validation of a Multimodal Artificial Intelligence-derived Digital Pathology-based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After Radical Prostatectomy in NRG/RTOG Trials.

European urology·2025
Same author

Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials.

JCO clinical cancer informatics·2025
Same author

Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes.

Clinical pharmacology and therapeutics·2025
Same author

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Genomic instability in bladder cancer increases with tumor stage and predicts patient outcomes. Higher fraction of genome altered correlates with worse prognosis in muscle-invasive bladder tumors.

Area of Science:

  • Genetics
  • Oncology
  • Genomics

Background:

  • Bladder cancer progression involves genetic alterations.
  • Genomic instability is a hallmark of cancer.
  • Understanding genomic alterations aids in predicting bladder cancer outcomes.

Purpose of the Study:

  • To evaluate associations between genomic instability measures and bladder cancer clinical phenotype.
  • To determine if genomic instability predicts patient outcomes in bladder cancer.

Main Methods:

  • Genome-wide copy number profiles were generated using array-based comparative genomic hybridization (CGH) for 98 bladder tumors.
  • Tumors varied in stage (pT(a), pT1, pT(2-4)) and grade (low/high).
  • Outcome analysis focused on muscle-invasive tumors with good (>2 years survival) versus bad (<2 years survival) prognosis.

Related Experiment Videos

Main Results:

  • Genomic instability and copy number alterations increased with tumor stage and predicted outcome.
  • Fraction of genome altered (FGA) differed significantly between tumor stages (p < 0.0003).
  • FGA was the sole independent predictor of outcome in muscle-invasive tumors (p = 0.002), with 71% classification success.

Conclusions:

  • Array-based CGH revealed high-resolution DNA copy number differences based on tumor stage and grade.
  • Fraction of genome altered is linked to worse outcomes in muscle-invasive bladder cancer.
  • Genomic instability measures enhance the predictive power for bladder tumor outcomes.